title: [A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
abstract: There have been few effective chemotherapeutic regimens for advanced gastric cancer with liver and intra-abdominal lymph node metastasis. A 78-year-old male patient was admitted to our hospital because of anorexia and abdominal discomfort. Gastroendoscopy showed a type 4 advanced gastric cancer in the antrum of the stomach. Histological study of biopsy specimens from the tumor revealed poorly differentiated adenocarcinoma. Examination by computed tomography and ultrasonography showed swollen paraaortic lymph nodes and liver metastasis. He was diagnosed as having advanced gastric cancer with liver and lymph node metastasis. This patient was treated weekly with an intraarterial 5-FU (500 mg) and MTX (100 mg) including AT-II by subcutaneously implanted port system placed into the celiac artery. Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC). After ten courses of treatment with PMC, the liver and lymph node metastases were reduced in size. This therapy was considered to be an effective treatment for advanced gastric cancer with liver and lymph node metastasis. The theoretical purpose of hypertensive chemotherapy used together with injection of angiotensin-II is to increase the delivery of anticancer drug to the target tumor tissue by increasing the blood flow in the tumor. We conclude that this chemotherapy is effective in cases of advanced gastric cancer with liver and lymph node metastasis from the viewpoints of toxicities, antitumor effect and QOL of the patient.
authors.affiliation: Dept. of Gastroenterology, Saiseikai Niigata Daini Hospital.
authors.forename: Toru
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Nomura
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Baba
authors.forename: Syun-ichi
authors.initials: S
authors.lastname: Hayashi
authors.forename: Hironobu
authors.initials: H
authors.lastname: Oota
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tomoteru
authors.initials: T
authors.lastname: Kamimura
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000368:Aged; D000804:Angiotensin II / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000556:secondary; D013274:Stomach Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage*
chemical_list: D000804:Angiotensin II; D005641:Tegafur; D005472:Fluorouracil; D008727:Methotrexate